WO2009044846A1 - 薬物誘発性リン脂質症の予測方法 - Google Patents

薬物誘発性リン脂質症の予測方法 Download PDF

Info

Publication number
WO2009044846A1
WO2009044846A1 PCT/JP2008/068034 JP2008068034W WO2009044846A1 WO 2009044846 A1 WO2009044846 A1 WO 2009044846A1 JP 2008068034 W JP2008068034 W JP 2008068034W WO 2009044846 A1 WO2009044846 A1 WO 2009044846A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
induced phospholipidosis
amount
predicting drug
drug
Prior art date
Application number
PCT/JP2008/068034
Other languages
English (en)
French (fr)
Inventor
Yoshitaka Tanaka
Kazuhiko Ikeda
Original Assignee
Kyushu University, National University Corporation
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University, National University Corporation, Astellas Pharma Inc. filed Critical Kyushu University, National University Corporation
Priority to EP08835363A priority Critical patent/EP2194141A4/en
Priority to CA2697988A priority patent/CA2697988A1/en
Priority to JP2009536096A priority patent/JP5062578B2/ja
Priority to US12/674,771 priority patent/US20110117588A1/en
Publication of WO2009044846A1 publication Critical patent/WO2009044846A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G01N2333/92—Triglyceride splitting, e.g. by means of lipase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

　本発明は、薬物誘発性リン脂質症の予測方法であって、哺乳動物細胞と被検化合物とを接触させる工程、該細胞外および／または細胞内のリソソーム酵素の量もしくは活性を測定するあるいは細胞内のＬＣ３の量を測定する工程、および該酵素の細胞外への分泌を促進したあるいは該蛋白質の量を増加させた被検化合物を、薬物誘発性リン脂質症を誘発し得る化合物として選択する工程を含む方法を提供する。
PCT/JP2008/068034 2007-10-04 2008-10-03 薬物誘発性リン脂質症の予測方法 WO2009044846A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08835363A EP2194141A4 (en) 2007-10-04 2008-10-03 METHOD FOR PREDICTING MEDICINE-INDUCED PHOSPHOLIPIDOSIS
CA2697988A CA2697988A1 (en) 2007-10-04 2008-10-03 Method of predicting drug-induced phospholipidosis
JP2009536096A JP5062578B2 (ja) 2007-10-04 2008-10-03 薬物誘発性リン脂質症の予測方法
US12/674,771 US20110117588A1 (en) 2007-10-04 2008-10-03 Method of predicting drug-induced phospholipidosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-261125 2007-10-04
JP2007261125 2007-10-04

Publications (1)

Publication Number Publication Date
WO2009044846A1 true WO2009044846A1 (ja) 2009-04-09

Family

ID=40526268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068034 WO2009044846A1 (ja) 2007-10-04 2008-10-03 薬物誘発性リン脂質症の予測方法

Country Status (5)

Country Link
US (1) US20110117588A1 (ja)
EP (1) EP2194141A4 (ja)
JP (1) JP5062578B2 (ja)
CA (1) CA2697988A1 (ja)
WO (1) WO2009044846A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013114233A (ja) * 2011-11-30 2013-06-10 Olympus Corp 画像処理装置、顕微鏡システム、画像処理方法、及び画像処理プログラム

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9610358B2 (en) * 2014-04-17 2017-04-04 Marker Gene Technologies, Inc Targeted pharmacological chaperones
WO2018213389A1 (en) * 2017-05-17 2018-11-22 Nextcea Inc. Inducing phospholipidosis for enhancing therapeutic efficacy
CN108929373A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一种共价键修饰哺乳动物atg8 同源物的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006112947A (ja) 2004-10-15 2006-04-27 Sumitomo Chemical Co Ltd 物質が有するホスホリピドーシス誘発能力の検定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2434445A (en) * 2006-01-13 2007-07-25 Cytokinetics Inc Assay for phospholipidosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006112947A (ja) 2004-10-15 2006-04-27 Sumitomo Chemical Co Ltd 物質が有するホスホリピドーシス誘発能力の検定方法

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"Dai 35 Kai Annual Meeting of the Japanese Society of Toxicology", 25 June 2008, article KAZUHIKO IKEDA ET AL.: "Shinki in vitro Phospholipidosis Screening-kei no Kochiku" *
"Meth. Enzymol.", vol. 70, article "Immunochemical Techniques"
ANDERSON N. ET AL: "Drug-induced phospholipidosis.", FEBS LETT., vol. 580, September 2006 (2006-09-01), pages 5533 - 5540, XP025232693 *
ATIENZAR F. ET AL: "Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.", TOXICOL. SCI., vol. 96, no. 1, March 2007 (2007-03-01), pages 101 - 114, XP003026555 *
BARITUSSIO A. ET AL: "Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes.", AM. J. PHYSIOL. LUNG CELL. MOL. PHYSIOL., vol. 281, November 2001 (2001-11-01), pages 1189 - 1199, XP003026552 *
BIOCHEM. PHARMACOL., vol. 53, 1997, pages 1521 - 32
BIOCHEM. PHARMACOL., vol. 62, 2001, pages 1661 - 73
BIOCHIM. BIOPHYS. ACTA, vol. 1631, 2003, pages 136 - 46
CELL BIOL. TOXICOL., vol. 19, 2003, pages 161 - 76
FUJIMURA H. ET AL: "Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.", EXP. TOXICOL. PATHOL., vol. 58, August 2007 (2007-08-01), pages 375 - 382, XP022155499 *
J. BIOCHEM, vol. 125, 1999, pages 1137 - 1143
KASAHARA T. ET AL: "Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential.", TOXICOL. SCI., vol. 90, no. 1, December 2005 (2005-12-01), pages 133 - 141, XP003026554 *
METHODS IN ENZYMOLOGY, vol. 80, 1981, pages 535 - 561
NIOI P. ET AL: "vitro detection of drug- induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.", TOXICOL. SCI., vol. 99, no. 1, September 2007 (2007-09-01), pages 162 - 173, XP003026556 *
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1
PROG. NEUROBIOL., vol. 60, 2000, pages 501 - 12
SCIENCE, vol. 122, 1952, pages 501
See also references of EP2194141A4 *
SEWELL R. B. ET AL: "Perhexilene: effects on hepatic lysosomal function in rats.", CLIN. EXP. PHARMACOL. PHYSIOL., vol. 16, January 1989 (1989-01-01), pages 25 - 32, XP003026553 *
THE EMBO JOURNAL, vol. 12, 1993, pages 5219 - 5223
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
TOXICOL. SCI., vol. 83, 2005, pages 282 - 92
TOXICOL. SCI., vol. 90, 2006, pages 133 - 41
VIROLOGY, vol. 8, 1959, pages 396

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013114233A (ja) * 2011-11-30 2013-06-10 Olympus Corp 画像処理装置、顕微鏡システム、画像処理方法、及び画像処理プログラム
US9632300B2 (en) 2011-11-30 2017-04-25 Olympus Corporation Image processing apparatus, microscope system, image processing method, and computer-readable recording medium

Also Published As

Publication number Publication date
CA2697988A1 (en) 2009-04-09
US20110117588A1 (en) 2011-05-19
JPWO2009044846A1 (ja) 2011-02-10
JP5062578B2 (ja) 2012-10-31
EP2194141A1 (en) 2010-06-09
EP2194141A4 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
WO2008083179A3 (en) Analyte devices and methods
WO2008019123A3 (en) Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
ZA201606403B (en) Pluripotent stem cell culture on micro-carriers
EP2212342A4 (en) ELECTROCHEMICAL ASSAY FOR THE DETECTION OF ENZYMES
WO2007123791A3 (en) Methods of determining cellular chemosensitivity
WO2010019439A3 (en) A predictor of when to harvest cells grown in a bioreactor
WO2007143104A8 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2012076553A3 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
WO2007082144A3 (en) B7-h1 and survivin in cancer
EP2335060A4 (en) ELECTROCHEMICAL BIOSENSOR STRUCTURE AND METHOD OF MEASUREMENT THEREWITH
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
DK1952103T3 (da) Fremgangsmåde til at veje med flere vejeceller
WO2011034935A3 (en) Transcription biomarkers of biological responses and methods
EP2535050A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2008051290A3 (en) Steroid responsive nucleic acid expression and prediction of disease activity
WO2011104517A3 (en) Capacitance detection in electrochemical assay
WO2011005289A3 (en) Methods and kits for measuring enzyme activity
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
HK1176097A1 (en) Methods and reagent kits for determining the activity of thioredoxin reductase and the uses thereof
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
WO2007075910A3 (en) Methods and compositions for detecting enzymatic activity
WO2009044846A1 (ja) 薬物誘発性リン脂質症の予測方法
WO2011119986A3 (en) Methods for culturing and analyzing cells
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08835363

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008835363

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2697988

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009536096

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12674771

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE